We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Agenus (AGEN) Up 51.6% Since Last Earnings Report?
Read MoreHide Full Article
It has been about a month since the last earnings report for Agenus (AGEN - Free Report) . Shares have added about 51.6% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Agenus due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
Agenus Earnings and Revenues Beat Estimates in Q1
Agenus reported first-quarter 2020 loss of 31 cents per share, narrower than the Zacks Consensus Estimate of a loss of 35 cents. However, the figure came in against the year-ago quarter’s earnings of 12 cents.
The company generated revenues of $15.1 million including non-cash royalties and other revenues, down from $80 million reported in the year-ago quarter. The top line too beat the Zacks Consensus Estimate of $12 million.
Quarterly Highlights
Research and development expenses decreased 9.5% year over year to $36.3 million. General and administrative expenses dipped 1.8% to $10.6 million.
Pipeline Update
Agenus announced that the FDA has granted a Fast Track status to the combination of its CTLA-4 antibody zalifrelimab and PD-1 antibody balstilimab for the treatment of patients with relapsed/refractory metastatic cervical cancer. Notably in April 2020, the FDA also granted a Fast Track designation to balstilimab for the treatment of advanced cervical cancer.
The company expects to file two biologics license applications (BLAs) seeking accelerated approval of the balstilimab + zalifrelimab combo and balstilimab monotherapy for metastatic cervical cancer.
In January 2020, Agenus initiated a phase I study on AGEN1223, a novel bi-specific antibody, designed to deplete regulatory T cells in the tumor microenvironment.
Notably, GlaxoSmithKline plc’s herpes zoster vaccine, Shingrix, which contains Agenus' proprietary immune adjuvant QS-21 Stimulon, achieved more than $2 billion in revenues during 2019.
Meanwhile, Agenus is advancing the clinical development of an allogeneic iNKT therapy for the treatment of cancer and COVID-19.
How Have Estimates Been Moving Since Then?
Estimates review followed an upward path over the past two months. The consensus estimate has shifted 10.1% due to these changes.
VGM Scores
At this time, Agenus has a subpar Growth Score of D, though it is lagging a bit on the Momentum Score front with an F. However, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Agenus has a Zacks Rank #1 (Strong Buy). We expect an above average return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Is Agenus (AGEN) Up 51.6% Since Last Earnings Report?
It has been about a month since the last earnings report for Agenus (AGEN - Free Report) . Shares have added about 51.6% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Agenus due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
Agenus Earnings and Revenues Beat Estimates in Q1
Agenus reported first-quarter 2020 loss of 31 cents per share, narrower than the Zacks Consensus Estimate of a loss of 35 cents. However, the figure came in against the year-ago quarter’s earnings of 12 cents.
The company generated revenues of $15.1 million including non-cash royalties and other revenues, down from $80 million reported in the year-ago quarter. The top line too beat the Zacks Consensus Estimate of $12 million.
Quarterly Highlights
Research and development expenses decreased 9.5% year over year to $36.3 million. General and administrative expenses dipped 1.8% to $10.6 million.
Pipeline Update
Agenus announced that the FDA has granted a Fast Track status to the combination of its CTLA-4 antibody zalifrelimab and PD-1 antibody balstilimab for the treatment of patients with relapsed/refractory metastatic cervical cancer. Notably in April 2020, the FDA also granted a Fast Track designation to balstilimab for the treatment of advanced cervical cancer.
The company expects to file two biologics license applications (BLAs) seeking accelerated approval of the balstilimab + zalifrelimab combo and balstilimab monotherapy for metastatic cervical cancer.
In January 2020, Agenus initiated a phase I study on AGEN1223, a novel bi-specific antibody, designed to deplete regulatory T cells in the tumor microenvironment.
Notably, GlaxoSmithKline plc’s herpes zoster vaccine, Shingrix, which contains Agenus' proprietary immune adjuvant QS-21 Stimulon, achieved more than $2 billion in revenues during 2019.
Meanwhile, Agenus is advancing the clinical development of an allogeneic iNKT therapy for the treatment of cancer and COVID-19.
How Have Estimates Been Moving Since Then?
Estimates review followed an upward path over the past two months. The consensus estimate has shifted 10.1% due to these changes.
VGM Scores
At this time, Agenus has a subpar Growth Score of D, though it is lagging a bit on the Momentum Score front with an F. However, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Agenus has a Zacks Rank #1 (Strong Buy). We expect an above average return from the stock in the next few months.